Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trials

• Main Authors: Romulo Colindres (Author), Valentine Wascotte (Author), Alain Brecx (Author), Christopher Clarke (Author), Caroline Hervé (Author), Joon Hyung Kim (Author), Myron J. Levin (Author), Lidia Oostvogels (Author), Toufik Zahaf (Author), Anne Schuind (Author), Anthony L. Cunningham (Author)
• Format: Book
• Published: Taylor & Francis Group, 2020-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

In two large clinical trials (ZOE-50 [NCT01165177] and ZOE-70 [NCT01165229]), two doses of the adjuvanted recombinant zoster vaccine (RZV) demonstrated >90% efficacy against herpes zoster in adults ≥50 years of age. Solicited adverse events (AEs) were collected for 7 days post-each dose in a stud...